General Hospital Of Thessaloniki Papageorgiou
- Address
- lock Available on a paid plan
General Hospital Of Thessaloniki Papageorgiou - Dermatological Research Center
General Hospital Of Thessaloniki Papageorgiou is actively engaged in advancing therapeutic options for complex dermatological conditions. The center specializes in conducting clinical research focused on inflammatory skin diseases and evaluating novel biologic treatments for conditions that significantly impact patient quality of life.
- Moderate to severe hidradenitis suppurativa clinical trials
- Novel biologic therapies including anti-inflammatory agents
- Phase 2 clinical efficacy studies in dermatology
The research team at this facility has particular expertise in managing and studying hidradenitis suppurativa (HS), a chronic inflammatory skin condition. Their participation in Phase 2b trials evaluating innovative treatments like eltrekibart demonstrates their commitment to finding superior therapeutic solutions for patients with moderate-to-severe disease, utilizing advanced clinical response measures such as HiSCR50 to assess treatment efficacy.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 15 therapeutic areas and 15 of 158 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 153 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 32 by active trials.
- 1AstraZeneca AB3active
lock +31 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB7trials
lock +23 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in General Hospital Of Thessaloniki Papageorgiou
lock Showing 1 of 116 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Double-Blind, Randomized Withdrawal Study of Subcutaneous Secukinumab for Long-Term Efficacy and Safety in Moderate to Severe Hidradenitis Suppurativa | Novartis Pharma AG | Phase III | Not Recruiting | Mar 2020 | Jun 2026 |
IMP list
lock Showing 1 of 158 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 9 | Unknown | 2024-04-12 | 2026-01-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.